# Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

> **NCT05300048** · PHASE1 · TERMINATED · sponsor: **Faeth Therapeutics** · enrollment: 34 (actual)

## Conditions studied

- Advanced Solid Tumor
- PIK3CA Mutation
- PTEN Loss of Function Mutation

## Interventions

- **DRUG:** Serabelisib
- **OTHER:** Insulin Suppressing Diet
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT05300048
- **Lead sponsor:** Faeth Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-22
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Program prioritization
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05300048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05300048, "Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05300048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*